PETACH TIKVA, Israel, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Nanox Imaging Ltd. (“Nanox” or the “Company”, Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will showcase technologies designed to enable earlier detection and broader access to care at the Radiological Society of North America (RSNA) 2026 Annual Meeting: Nanox.ARC X, a TIME Best Inventions of 2026 honoree and FDA-cleared multi-source digital tomosynthesis system powered by proprietary digital X-ray technology, and Nanox.AI, FDA-cleared AI that analyzes routine CT scans to identify early signs of chronic conditions. The Company will also preview new innovations in development. RSNA is taking place November 29 to December 2, 2026, Chicago, IL.
PETACH TIKVA, Israel, Nov. 16, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), a leader in innovative medical imaging technology, today announced that it will report its financial results for the quarter ended September 30, 2026, before market open on Wednesday, November 25, 2026. Erez Meltzer, Chief Executive Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m.
Building on Nanox.AI's existing deployment in Athens, the agreement supports commercial expansion in Greece through Medworks ' established market presence.
Collaboration builds on Dosy Health's established relationships with Mahidol University, Thammasat University and hospitals within the BDMS network, supporting planned distribution and commercialization in Thailand PETACH TIKVA, Israel, [DATE] (GLOBE NEWSWIRE) -- Nano-X Imaging Ltd. (NASDAQ: NNOX) (“Nanox” or the “Company”), a leader in innovative medical imaging technology , today announced that its subsidiary, Nanox AI Ltd.
The Board approved plan target s a 25%–30% reduction in annualized operating expenses, compared to annualized 2026 GAAP and non-GAAP operating expenses, once fully implemented, expected by the end of Q 1 202 7 Cost reduction aims to a dvanc e four strategic priorities: Nanox.ARC and N anox Imaging Network (N IN ) commercialization; commercial partnerships and business development; operational efficiency; and strengthening financial resources Cost initiatives are intended to improve resource s allocation while preserving critical product-development , regulatory and commercial capabilities PETACH TIKVA, Israel, Nov. 09, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, today announced that the Board of Directors of the Company (the “Board”) has approved a plan to reduce costs and improve operational efficiency. The plan approved by the Board is in addition to the Company's previously announced cost reduction initiatives, including the restructuring of its South Korea operations, and is expected to reduce the Company's operating expenses, extend its cash resources and enable the Company to focus on its core priorities.
PETACH TIKVA, Israel, Nov. 9, 2026 (GLOBE NEWSWIRE) -- Nanox Imaging Ltd. (“Nanox” or the “Company”, NASDAQ: NNOX), a leader in innovative medical imaging technology, today announced that its wholly owned subsidiary, USARAD Holdings, Inc. (“USARAD”), is expanding its existing collaboration with AZmed , a medical imaging AI company specializing in AI-powered X-ray analysis, to further integrate AZmed's X-ray AI solutions into USARAD's radiology workflows through Nanox Marketplace.
PETACH TIKVA, Israel , Nov . 2 , 2026 (GLOBE NEWSWIRE) -- Nanox Imaging Ltd. (“Nanox” or the “Company”, NASDAQ: NNOX), a leader in innovative medical imaging technology, today announced that updated clinical data on Nanox AI Ltd 's ("Nanox.AI") aortic valve calcification (AVC) AI solution w as presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference , taking place October 31 to November 3, 2026, in San Diego, California.
PETACH TIKVA, Israel, Oct. 16, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today provided a brief business update and furnished certain preliminary unaudited financial data for the third quarter ended September 30, 2026. The preliminary figures are estimates based on currently available information, are preliminary and unaudited, and are subject to change upon completion of the Company's financial close process, final adjustments, management review and other internal procedures, and review by its independent auditors.
Agreement aims to expand the commercial reach of Nanox.AI's Bone Solution in the Italian healthcare market. Collaboration leverages Tecnologie Avanzate's 50 years of experience in the Italian medical technology market, established healthcare industry relationships, and expertise in introducing advanced medical technologies.
Nanox.ARC X recognized among the “world's most groundbreaking innovations” and for its approach to making advanced medical imaging more accessible